Form 8-K - Current report:
SEC Accession No. 0001193125-25-055602
Filing Date
2025-03-17
Accepted
2025-03-17 16:01:13
Documents
13
Period of Report
2025-03-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K d938905d8k.htm   iXBRL 8-K 23825
  Complete submission text file 0001193125-25-055602.txt   148938

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kalv-20250313.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20250313_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20250313_pre.xml EX-101.PRE 11709
15 EXTRACTED XBRL INSTANCE DOCUMENT d938905d8k_htm.xml XML 3855
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 25744286
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)